CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Core Insights - CRISPR Therapeutics will present at the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 10:30 a.m. ET [1] - A live webcast of the presentation will be available on the company's website, with a replay archived for 14 days [2] Company Overview - CRISPR Therapeutics has transitioned from a research-stage company to a leader in gene-based medicines, celebrating the approval of the first CRISPR-based therapy [3] - The company has a diverse portfolio targeting various diseases, including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases [3] - The first CRISPR/Cas9 gene-edited therapy was advanced into clinical trials in 2018 for sickle cell disease and transfusion-dependent beta thalassemia [3] - CASGEVY (exa-cel) received approval in several countries starting in late 2023 for treating eligible patients with these conditions [3] - CRISPR Therapeutics has formed strategic partnerships with leading companies, including Vertex Pharmaceuticals, to enhance its efforts [3] - The company is headquartered in Zug, Switzerland, with R&D operations in Boston, Massachusetts, and San Francisco, California [3]